Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on October 23, 2025. The filing discloses preliminary clinical data from the VS-7375 Phase 1/2a dose escalation trial for patients with KRAS G12D mutant solid tumors. VS-7375 is an oral KRAS G12D inhibitor developed through a collaboration with GenFleet Therapeutics.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or quarterly results.
Material Changes and Clinical Updates
- Safety Profile: VS-7375 cleared 400 mg and 600 mg daily monotherapy doses with no dose-limiting toxicities (DLTs). No nausea, diarrhea, or vomiting greater than Grade 1 were reported in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) patients.
- Efficacy Data: Among five efficacy-evaluable patients with at least one scan, four demonstrated tumor reduction and remain on treatment. Remaining patients have not yet reached their first response assessment.
- Trial Progression: Monotherapy dose escalation is continuing to 900 mg daily. The company has initiated enrollment for the first combination cohort evaluating VS-7375 with cetuximab in advanced solid tumors, including colorectal cancer.
Guidance, Outlook, and Risks
Verastem plans to select a recommended Phase 2 dose following the ongoing monotherapy dose escalation to 900 mg daily. The company intends to advance efficacy and safety analysis in patient expansion cohorts for advanced PDAC and NSCLC. An interim safety and efficacy update is expected in the first half of 2026. The filing includes standard forward-looking statement disclaimers regarding risks that could cause actual results to differ materially from expectations, including trial timing and clinical outcomes.
Key Facts for Investor Verification
- Confirm the specific tumor reduction percentages and duration of response for the four responding patients.
- Verify the timeline for the 900 mg daily dose escalation and the selection of the recommended Phase 2 dose.
- Monitor enrollment progress for the VS-7375 and cetuximab combination cohort in colorectal cancer.
- Review the upcoming interim data release scheduled for the first half of 2026.
- Assess the financial impact of the collaboration with GenFleet Therapeutics on future cash burn and funding needs.